Difference between revisions of "Invasive breast cancer"

Jump to navigation Jump to search
Line 156: Line 156:


*Overview  
*Overview  
**A category of breast carcinomas defined by gene expression profiling
**Somewhere between 15-30% of breast carcinomas.
**Somewhere between 15-30% of breast carcinomas.
**A category of breast carcinomas defined by gene expression profiling
**Can be identified by immunohistochemistry - basal markers (CK14, p63, calponin, SMA)
**Can be identified by immunohistochemistry - basal markers (CK14, p63, calponin, SMA)
**Not derived from myoepithelial cells, merely express a phenotype more in keeping with basal cells than ductal cells
**Not derived from myoepithelial cells, merely express a phenotype more in keeping with basal cells than ductal cells
Line 188: Line 188:
**Basal-like breast cancer is a heterogeneous group.
**Basal-like breast cancer is a heterogeneous group.
**The behaviour of basal-like breast cancer appears to fall into two groups:
**The behaviour of basal-like breast cancer appears to fall into two groups:
***The tumours that do not metastasise have a better prognosis than other types of breast carcinoma.
***The tumours that are by nature low grade (ie adenoid cystic carcinoma) and/or do not metastasise have a better prognosis than other types of breast carcinoma.
***Tumours with early metastasis may behave more aggressively
***The tumours with early metastasis that may behave more aggressively
****Hematogenous spread -greater tendency to metastasise to visceral sites associated with poorer prognosis (such as lung and brain) instead of to nodes and bone.
****Hematogenous spread -greater tendency to metastasise to visceral sites (notably lung and brain) instead of to nodes and bone.
**Many have a complete response to chemotherapy and survival rates similar to typical breast cancer
**Many have a complete response to chemotherapy and survival rates similar to typical breast cancer
**Non-complete response to chemotherapy is associated with low survival at 5 years.
**Non-complete response to chemotherapy is associated with low survival at 5 years.
653

edits

Navigation menu